Annals of Emergency Medicine
Volume 55, Issue 2 , Pages 226-227 , February 2010

Response to: “A Graphic Reanalysis of the NINDS Trial”

  • Jeffrey L. Saver, MD

      Affiliations

    • Department of Neurology and Stroke Center, University of California, Los Angeles, Los Angeles, CA
    • ,
  • Jeffrey Gornbein, PhD

      Affiliations

    • Department of Biomathematics, University of California, Los Angeles, Los Angeles, CA
    • ,
  • Sidney Starkman, MD

      Affiliations

    • Departments of Emergency Medicine and Neurology, and Stroke Center, University of California, Los Angeles, Los Angeles, CA

References 

  1. Hoffman JR, Schriger DL. A graphical reanalysis of the NINDS trial. Ann Emerg Med. 2009;54:329–336
  2. Tufte E. The Visual Display of Quantitative Information. 2nd ed.. Cheshire, Connecticut: Graphics Press LLC; 2001;
  3. Saver J, Starkman S. Impact of treatment on individual patients in the two NINDS-TPA trials: normalized change in NIHSS score confirms benefit graphically and statistically. Stroke. 2009;40:e405
  4. Saver JL, Yafeh B. Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials. Stroke. 2007;38:414–416
  5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–1329
  6. Acker JE, Pancioli AM, Crocco TJ, et al. Implementation strategies for emergency medical services within stroke systems of care: a policy statement from the American Heart Association/ American Stroke Association Expert Panel on Emergency Medical Services Systems and the Stroke Council. Stroke. 2007;38:3097–3115

 Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. Dr. Saver is an employee of the University of California, which holds a patent on retriever devices for stroke; is a scientific consultant regarding trial design and conduct to CoAxia, Concentric Medical, Talecris, Ferrer, AGA Medical, BrainsGate, PhotoThera, and Cygnis (all modest); has received lecture honoraria from Ferrer and Boehringer Ingelheim (modest); received devices for use in an NIH multicenter clinical trial from Concentric Medical (modest); has declined consulting/honoraria monies from Genentech since 2002; has declined serving as a medicolegal expert in tPA litigation since 2002; is a site investigator in multicenter trials sponsored by AGA Medical, Vernalis, Paion, Lundbeck, and Neurobiological Technologies for which the UC Regents received payments based on the clinical trial contracts for the number of subjects enrolled; is a site investigator in the NIH IRIS, CLEAR, IMS 3, SWISS, and SAMPRISS multicenter clinical trials for which the UC Regents receive payments based on the clinical trial contracts for the number of subjects enrolled; administers stroke thrombolytic therapy in his practice (<5% of effort); and is funded by NIH-NINDS Awards P50 NS044378 and U01 NS 44364.

 Dr. Gornbein is an employee of the University of California, which holds a patent on retriever devices for stroke.

 Dr. Starkman has served as a prominent medicolegal expert defender of emergency physicians in acute stroke tPA litigation; is an employee of the University of California, which holds a patent on retriever devices for stroke; has been a site investigator in multicenter trials sponsored by Vernalis, Paion, Lundbeck, and Neurobiological Technologies for which the UC Regents received payments based on the clinical trial contracts for the number of subjects enrolled; is a site investigator in a multicenter registry run by Concentric for which the UC Regents received payments based on the clinical trial contracts for the number of subjects enrolled; is a site investigator in the NIH CLEAR and IMS 3 multicenter clinical trials for which the UC Regents receive payments based on the clinical trial contracts for the number of subjects enrolled; administers stroke thrombolytic therapy in his practice (<5% of effort); and is funded by NIH-NINDS Awards P50 NS044378 and U01 NS 44364.

PII: S0196-0644(09)01614-X

doi: 10.1016/j.annemergmed.2009.09.024

Annals of Emergency Medicine
Volume 55, Issue 2 , Pages 226-227 , February 2010

Article Tools